compare glp-1 drugs New oral drug delivers up to 12% weight loss in 36 weeks Comparing Ozempic, Wegovy and Other

87 Obesity is thought to exert an effect on the HPG axis through the role of excess fat in the aromatization of androgen to estrogen

Obesity is the most common cause of obstructive sleep apnea because excess fat around the neck and airway increases resistance to airflow during sleep

The ESSENCE trial will provide valuable data on the maintenance of histological benefits over 240 weeks of continuous treatment, but long-term extension studies and off-treatment follow-up protocols are needed to characterize rebound kinetics

[DOI] [PubMed] [Google Scholar] 143.Ghusn W, Hurtado MD

26 The drug that has advanced furthest through development, in fact all the way to market, is Eli Lilly and Companys (Indianapolis, Indiana, USA) tirzepatide (LY3298176), a unimolecular dual GIP/GLP-1 RA

Curr Treat Options Cardiovasc Med (2017) 19(3)